BrainXell, Inc. Welcomes Katherine Vega Stultz as New CEO and Board Director

BrainXell, Inc. Appoints Katherine Vega Stultz as CEO

MADISON, Wis., July 10, 2025 — In an exciting development for the biotechnology sector, BrainXell, Inc., known for its groundbreaking advancements in iPSC-based CNS disease models and regenerative cell therapies, has announced the appointment of Katherine Vega Stultz as its new Chief Executive Officer and Board Director. This decision marks a significant step forward for the company as it seeks to enhance its leadership and expertise in therapeutic developments.

Katherine Vega Stultz is not new to the challenges and opportunities of the biotech landscape; she brings with her over two decades of profound experience in advancing therapeutics across a diverse array of modalities and diseases. Stultz's leadership background encompasses various roles in strategy, clinical development, and commercialization. Her track record in assembling high-performing teams has been instrumental in moving therapies from laboratory research to real-world applications.

Dr. Su-Chun Zhang, the Founder and Advising Chief Scientific Officer at BrainXell, expressed enthusiasm about the new appointment, stating, "Katherine's leadership will help us accelerate BrainXell's growth as a force in neuroscience, advancing both cutting-edge research tools and a promising therapeutic pipeline to address the complexities of neurological disease."

At BrainXell, Ms. Stultz will spearhead the company's next growth phase, building upon its innovative platform that generates subtype-specific, functionally mature neurons from human iPSCs. This proprietary technology is utilized worldwide by researchers striving to advance discovery in critical areas such as Amyotrophic Lateral Sclerosis (ALS), Parkinson’s disease, and chronic pain. Notably, these developments form the backbone of BrainXell's pipeline dedicated to regenerative therapies.

"BrainXell's science and technology is rooted in understanding stem cell technology and applying this to a variety of neural cell subtypes," Stultz said. "This promising approach has significant potential for application across many neurological conditions. I'm honored to lead a dedicated team committed to finding solutions for patients with neurological disorders who often face limited or no effective treatment options."

The vision of BrainXell is clear—it aims to bridge the gap between research advancements and direct patient impact. The company is resolute in its commitment to providing biologically sophisticated tools and therapies that resonate with the complexities of human neurobiology, especially addressing the urgent needs of patients in clinical settings.

As BrainXell embarks on this new chapter under Stultz’s leadership, the biotechnology community watches closely, hopeful for the innovations that will emerge from the company aimed at improving lives through better treatment options for neurological diseases. Through her extensive expertise and guidance, Katherine Vega Stultz is poised to lead BrainXell toward a future filled with promise and transformative healthcare solutions.